The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation

Cancer Research

Volumn 67, Issue 9, 2007, Pages 4287-4294

  Follo, Matilde Y ^a   Mongiorgi, Sara ^a   Bosi, Costanza ^b   Cappellini, Alessandra ^d   Finelli, Carlo ^b   Chiarini, Francesca ^a   Papa, Veronica ^a   Libra, Massimo ^e   Martinelli, Giovanni ^b   Cocco, Lucio ^a   Martelli, Alberto M ^a,b,c  

^a Dipartimento di Scienze Anatomiche Umane e Fisiopatologia dell'Apparato Locomotore   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c CNR   (Italy)

^d UNIVERSITY OF CASSINO AND SOUTHERN LAZIO   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; PROTEIN P70; RAPAMYCIN;

ADULT; AGED; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; AGED; ANTIBODIES; ANTIBODY SPECIFICITY; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINEAGE; CELL SURVIVAL; FEMALE; HL-60 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RISK FACTORS; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 34249308840     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-4409     Document Type: Article

References (50)

1. Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006;7:606-19.
2. Kornblau SM, Womble M, Qiu YH, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia Blood 2006;108:2358-65.
3. McCubrey JA, Steelman LS, Abrams SL, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006;46:249-79.
4. Kim D, Cheng GZ, Lindsley CW, Yang H, Cheng JQ. Targeting the phosphatidylinositol-3 kinase/Akt pathway for the treatment of cancer. Curr Opin Investig Drugs 2005;6:1250-8.
5. Bellacosa A, Kumar CC, Di Cristofano A, Testa JR. Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res 2005;94:29-86.
6. Stauffer F, Holzer P, Garcia-Echeverria C. Blocking the PI3K/PKB pathway in tumor cells. Curr Med Chem AntiCanc Agents 2005;5:449-62.
7. Kharas MG, Fruman DA. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res 2005;65:2047-53.
8. Samstag Y, Nebl G. Ras initiates phosphatidyl-inositol-3-kinase (PI3K)/PKB mediated signalling pathways in untransformed human peripheral blood T lymphocytes. Adv Enzyme Regul 2005;45:52-62.
9. Martelli AM, Nyakern M, Tabellini G, et al. Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia Leukemia 2006;20:911-28.
10. Schade AE, Powers JJ, Wlodarski MW, Maciejewski JP. Phosphatidylinositol- 3-phosphate kinase pathway activation protects leukemic large granular lymphocytes from undergoing homeostatic apoptosis. Blood 2006;107:4834-40.
11. Grandage VL, Gale RE, Linch DC, Khwaja A. PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-κB, MAPK, and p53 pathways. Leukemia 2005;19:586-94.
12. Zeng Z, Samudio IJ, Zhang W, et al. Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia. Cancer Res 2006;66:3737-46.
13. Brandts CH, Sargin B, Rode M, et al. Constitutive activation of Akt by Flt3 internal tandem duplications is necessary for increased survival, proliferation, and myeloid transformation. Cancer Res 2005;65:9643-50.
14. Martelli AM, Tabellini G, Bortul R, et al. Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias. Histol Histopathol 2005;20:239-52.
15. Tee AR, Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol 2005;16:29-37.
16. Xu RH, Pelicano H, Zhang H, Giles FJ, Keating MJ, Huang P. Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells. Leukemia 2005;19:2153-8.
17. Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006;66:6589-97.
18. Braun T, Carvalho G, Coquelle A, et al. NF-κB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome. Blood 2006;107:1156-65.
19. Katsoulidis E, Li Y, Yoon P, et al. Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes. Cancer Res 2005;65:9029-37.
20. Tehranchi R, Fadeel B, Schmidt-Mende J, et al. Antiapoptotic role of growth factors in the myelodysplastic syndromes: concordance between in vitro and in vivo observations. Clin Cancer Res 2005;11:6291-9.
21. Navas TA, Mohindru M, Estes M, et al. Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors. Blood 2006;108:4170-7.
22. Nyakern M, Tazzari PL, Finelli C, et al. Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 2006;20:230-8.
23. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51:188-99.
24. Greenberga P, Cox C, Le Beau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-88.
25. Malaponte G, Libra M, Gangemi P, et al. Detection of BRAF gene mutation in primary choroidal melanoma tissue. Cancer Biol Ther 2006;5:225-7.
26. Nissen-Druey C, Tichelli A, Meyer-Monard S. Human hematopoietic colonies in health and disease. Acta Haematol 2005;113:5-96.
27. Mantovani I, Cappellini A, Tazzari PL, et al. Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells. J Cell Physiol 2006;207:836-44.
28. Tabellini G, Cappellini A, Tazzari PL, et al. Phosphoinositide 3-kinase/Akt involvement in arsenic trioxide resistance of human leukemia cells. J Cell Physiol 2005;202:623-34.
29. Ricciardi MR, McQueen T, Chism D, et al. Quantitative single cell determination of ERK phosphorylation and regulation in relapsed and refractory primary acute myeloid leukemia. Leukemia 2005;19:1543-9.
30. Knapp W, Strobl H, Majdic O. Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis. Cytometry 1994;18:187-98.
31. Kowal-Vern A, Mazzella FM, Cotelingam JD, Shrit MA, Rector JT, Schumacher HR. Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases. Am J Hematol 2000;65:5-13.
32. Ikezoe T, Nishioka C, Bandobashi K, et al. Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res. In press 2007.
33. Bousquet M, Recher C, Queleen C, Demur C, Payastre B, Brousset P. Assessement of somatic mutations in phosphatidylinositol 3-kinase gene in human lymphoma and acute leukaemia. Br J Haematol 2005;131:411-3.
34. Liu Z, Roberts TM. Human tumor mutants in the p110α subunit of PI3K. Cell cycle 2006;5:675-7.
35. Min YH, Eom JI, Cheong JW, et al. Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable. Leukemia 2003;17:995-7.
36. Sujobert P, Bardet V, Cornillet-Lefebvre P, et al. Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia. Blood 2005;106:1063-6.
37. Catenacci DV, Schiller GJ. Myelodysplastic syndromes: a comprehensive review. Blood Rev 2005;19:301-9.
38. Cocco L, Manzoli L, Palka G, Martelli AM. Nuclear phospholipase Cβ1, regulation of the cell cycle and progression of acute myeloid leukemia. Adv Enzyme Regul 2005;45:126-35.
39. Lo Vasco VR, Follo MY, Cocco L. Reply to Herens et al. Leukemia 2006;20:522-3.
40. Follo MY, Bosi C, Finelli C, et al. Real-time PCR as a tool for quantitative analysis of PI-PLCβ1 gene expression in myelodysplastic syndrome. Int J Mol Med 2006;18:267-71.
41. Giles FJ, Albitar M. Mammalian target of rapamycin as a therapeutic target in leukemia. Curr Mol Med 2005;5:653-61.
42. Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005;16:525-37.
43. Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia Blood 2005;105:2527-34.
44. Yee KW, Zeng Z, Konopleva M, et al. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin Cancer Res 2006;12:5165-73.
45. Platzbecker U, Haase M, Herbst R, et al. Activity of sirolimus in patients with myelodysplastic syndrome - results of a pilot study. Br J Haematol 2005;128:625-30.
46. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307:1098-101.
47. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006;22:159-68.
48. Billottet C, Grandage VL, Gale RE, et al. A selective inhibitor of the p1106 isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene 2006;25:6648-59.
49. Barragan M, de Frias M, Iglesias-Serret D, et al. Regulation of Akt/PKB by phosphatidylinositol 3-kinase-dependent and -independent pathways in B-cell chronic lymphocytic leukemia cells: role of protein kinase Cβ. J Leukoc Biol 2006;80:1473-9.
50. Rizvi MA, Ghias K, Davies KM, et al. Enzastaurin (LY317615), a protein kinase Cβ inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006;5:1783-9.